BSE Live
Dec 29, 16:01Prev. Close
2009.95
Open Price
2043.00
Bid Price (Qty.)
2000.00 (6)
Offer Price (Qty.)
2028.20 (5)
NSE Live
Dec 29, 15:44Prev. Close
2010.60
Open Price
2012.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
2009.70 (452)
| Key Financial Ratios of Glenmark Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 37.11 | -53.22 | 10.53 | 33.37 | 34.38 | |
| Diluted EPS (Rs.) | 37.11 | -53.22 | 10.53 | 33.37 | 34.38 | |
| Cash EPS (Rs.) | 54.33 | -30.18 | 35.04 | 52.46 | 50.10 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 313.60 | 278.09 | 348.70 | 334.48 | 250.36 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 313.60 | 278.09 | 348.70 | 334.48 | 250.36 | |
| Revenue from Operations/Share (Rs.) | 472.08 | 418.62 | 460.36 | 436.08 | 387.85 | |
| PBDIT/Share (Rs.) | 87.36 | 72.13 | 91.97 | 88.14 | 75.65 | |
| PBIT/Share (Rs.) | 70.13 | 51.50 | 70.31 | 70.89 | 59.93 | |
| PBT/Share (Rs.) | 49.58 | 1.29 | 30.78 | 51.08 | 48.99 | |
| Net Profit/Share (Rs.) | 37.11 | -50.80 | 13.37 | 35.21 | 34.38 | |
| NP After MI And SOA / Share (Rs.) | 37.11 | -53.21 | 10.53 | 33.37 | 34.38 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 18.50 | 17.22 | 19.97 | 20.21 | 19.50 | |
| PBIT Margin (%) | 14.85 | 12.30 | 15.27 | 16.25 | 15.45 | |
| PBT Margin (%) | 10.50 | 0.30 | 6.68 | 11.71 | 12.63 | |
| Net Profit Margin (%) | 7.86 | -12.13 | 2.90 | 8.07 | 8.86 | |
| NP After MI And SOA Margin (%) | 7.86 | -12.71 | 2.28 | 7.65 | 8.86 | |
| Return on Networth/Equity (%) | 11.83 | -19.13 | 3.13 | 10.36 | 13.73 | |
| Return on Capital Employed (%) | 19.62 | 17.01 | 13.84 | 16.13 | 14.83 | |
| Return on Assets (%) | 6.52 | -10.45 | 1.53 | 5.51 | 6.21 | |
| Total Debt/Equity (X) | 0.25 | 0.13 | 0.46 | 0.40 | 0.66 | |
| Asset Turnover Ratio (%) | 0.88 | 0.70 | 0.71 | 0.42 | 0.43 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.56 | 1.28 | 1.96 | 1.77 | 1.75 | |
| Quick Ratio (X) | 1.05 | 0.84 | 1.37 | 1.23 | 1.21 | |
| Inventory Turnover Ratio (X) | 4.81 | 1.15 | 1.31 | 1.85 | 1.85 | |
| Dividend Payout Ratio (NP) (%) | 6.73 | -4.69 | 23.73 | 7.49 | 7.27 | |
| Dividend Payout Ratio (CP) (%) | 4.60 | -7.66 | 7.76 | 4.93 | 4.99 | |
| Earnings Retention Ratio (%) | 93.27 | 104.69 | 76.27 | 92.51 | 92.73 | |
| Cash Earnings Retention Ratio (%) | 95.40 | 107.66 | 92.24 | 95.07 | 95.01 | |
| Coverage Ratios | ||||||
| Interest Coverage Ratios (%) | 11.90 | 3.94 | 7.42 | 8.34 | 6.05 | |
| Interest Coverage Ratios (Post Tax) (%) | 11.90 | 3.94 | 7.42 | 8.34 | 6.05 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 43,947.27 | 26,350.45 | 16,364.27 | 15,087.86 | 16,656.12 | |
| EV/Net Operating Revenue (X) | 3.30 | 2.23 | 1.26 | 1.23 | 1.52 | |
| EV/EBITDA (X) | 17.83 | 12.95 | 6.31 | 6.07 | 7.80 | |
| MarketCap/Net Operating Revenue (X) | 3.26 | 2.29 | 1.01 | 1.01 | 1.20 | |
| Retention Ratios (%) | 93.26 | 104.69 | 76.26 | 92.50 | 92.72 | |
| Price/BV (X) | 4.91 | 3.44 | 1.38 | 1.37 | 1.86 | |
| Price/Net Operating Revenue | 3.26 | 2.29 | 1.01 | 1.01 | 1.20 | |
| Earnings Yield | 0.02 | -0.06 | 0.02 | 0.08 | 0.07 |
23.12.2025
04.12.2025
Glenmark Consolidated September 2025 Net Sales at Rs 6,046.87 crore, up 76.1% Y-o-Y
03.12.2025
24.11.2025
Glenmark Standalone September 2025 Net Sales at Rs 1,538.66 crore, down 41.63% Y-o-Y
04.12.2025
Glenmark Consolidated September 2025 Net Sales at Rs 6,046.87 crore, up 76.1% Y-o-Y
24.11.2025
Glenmark Standalone September 2025 Net Sales at Rs 1,538.66 crore, down 41.63% Y-o-Y
27.05.2025
Glenmark Standalone March 2025 Net Sales at Rs 2,009.49 crore, down 6.46% Y-o-Y
04.03.2025
Glenmark Consolidated December 2024 Net Sales at Rs 3,387.55 crore, up 35.14% Y-o-Y
08.07.2022
Glenmark Pharmaceuticals Q1 PAT may dip 41.8% YoY to Rs 178.4 cr: Prabhudas Lilladher
14.04.2022
Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher
13.01.2022
Glenmark Pharmaceuticals Q3 PAT seen up 17.8% YoY to Rs 292.4 cr: Prabhudas Lilladher
06.10.2021
Glenmark Pharmaceuticals Q2 PAT seen up 18.4% YoY to Rs 269.5 cr: Prabhudas Lilladher
31.05.2019
Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell
09.02.2018
Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue
28.07.2017
31.07.2015